Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential calcipotriol and fluticasone therapy in pediatric plaque psoriasis
ChiCTR2300077162Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of calcipotriol and fluticasone propionate in plaque psoriasis and psoriasis (2 arms), sponsored by Beijing Children's Hospital. Primary endpoint: PASI 75 response rate at week 8. Planned start May 2023; status: not yet recruiting.
02
Drugs
calcipotriolfluticasone propionate
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on ChiCTR2300077162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077162.